GA
PCRX icon

Gagnon Advisors’s Pacira BioSciences PCRX Stock Holding History

Gagnon Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.97M Buy
352,637
+91,729
+35% +$2.04M 5.86% 8
2025
Q4 		$6.75M Buy
260,908
+47,506
+22% +$1.13M 4.29% 11
2025
Q3 		$5.5M Hold
213,402
– – 3.4% 14
2025
Q2 		$5.1M Buy
213,402
+80,012
+60% +$2.02M 3.43% 14
2025
Q1 		$3.31M Hold
133,390
– – 2.34% 19
2024
Q4 		$2.51M Hold
133,390
– – 1.61% 23
2024
Q3 		$2.01M Hold
133,390
– – 1.3% 24
2024
Q2 		$3.82M Hold
133,390
– – 2.91% 19
2024
Q1 		$3.9M Hold
133,390
– – 3.38% 15
2023
Q4 		$4.5M Sell
133,390
-46,941
-26% -$1.37M 3.93% 14
2023
Q3 		$5.53M Hold
180,331
– – 4.63% 10
2023
Q2 		$7.23M Hold
180,331
– – 4.84% 9
2023
Q1 		$7.36M Hold
180,331
– – 4.94% 7
2022
Q4 		$6.96M Hold
180,331
– – 4.7% 10
2022
Q3 		$9.59M Sell
180,331
-55,114
-23% -$3.06M 6.21% 3
2022
Q2 		$13.7M Sell
235,445
-15,695
-6% -$1.03M 8.31% 1
2022
Q1 		$19.2M Hold
251,140
– – 8.83% 1
2021
Q4 		$15.1M Buy
251,140
+10,998
+5% +$606K 6% 2
2021
Q3 		$13.4M Buy
240,142
+26,925
+13% +$1.55M 5.33% 5
2021
Q2 		$12.9M Buy
213,217
+19,357
+10% +$1.23M 4.92% 6
2021
Q1 		$13.6M Hold
193,860
– – 5.59% 4
2020
Q4 		$11.6M Hold
193,860
– – 5.21% 6
2020
Q3 		$11.7M Hold
193,860
– – 7.15% 3
2020
Q2 		$10.2M Hold
193,860
– – 7.32% 4
2020
Q1 		$6.5M Hold
193,860
– – 6.07% 4
2019
Q4 		$8.78M Hold
193,860
– – 4.92% 8
2019
Q3 		$7.38M Buy
193,860
+86,448
+80% +$3.45M 4.58% 7
2019
Q2 		$4.67M Buy
+107,412
New +$4.56M 2.67% 21

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gagnon Advisors's PCRX Position: Q1 2026 in Review

Gagnon Advisors increased its Pacira BioSciences (PCRX) stake by 35% in Q1 2026, buying an estimated $2.04M and bringing the position to 352,637 shares worth $7.97M. The position accounts for 5.86% of the portfolio, ranked #8.

Gagnon Advisors first reported a position in PCRX in Q2 2019 and has held it in 28 quarters since. The position peaked at $19.2M in Q1 2022. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Gagnon Advisors held 352,637 shares of Pacira BioSciences worth $7.97M as of Q1 2026.
  • Gagnon Advisors bought 91,729 Pacira BioSciences shares in Q1 2026, an estimated $2.04M.
  • Pacira BioSciences made up 5.86% of Gagnon Advisors's portfolio in Q1 2026, its #8 holding.
  • Gagnon Advisors first reported a position in Pacira BioSciences in Q2 2019 and has held it in 28 quarters since.
  • Gagnon Advisors's Pacira BioSciences position peaked at $19.2M in Q1 2022.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Gagnon Advisors's 13F filing for Q1 2026, filed 22 Apr 2026.